Diurnal cortisol and survival in epithelial ovarian cancer

Psychoneuroendocrinology

Volumn 53, Issue , 2015, Pages 256-267

  Schrepf, Andrew ^a   Thaker, Premal H ^b   Goodheart, Michael J ^c   Bender, David ^c   Slavich, George M ^d,e   Dahmoush, Laila ^c   Penedo, Frank ^f   DeGeest, Koen ^g   Mendez, Luis ^h   Lubaroff, David M ^e,i,j   Cole, Steven W ^d,e,k   Sood, Anil K ^l   Lutgendorf, Susan K ^a,c,j  

^a The University of Iowa   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^h FLORIDA INTERNATIONAL UNIVERSITY   (United States)

ⁱ UNIVERSITY OF IOWA   (United States)

^j UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

more..

Author keywords

Biological markers; Chronobiology disorders; Hydrocortisone; Inflammation; Ovarian neoplasms

Indexed keywords

HYDROCORTISONE; INTERLEUKIN 6; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; HORMONE DETERMINATION; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PROSPECTIVE STUDY; SALIVA LEVEL; SURVIVAL RATE; SURVIVAL TIME; AGED; ASCITES FLUID; CHEMISTRY; CIRCADIAN RHYTHM; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM; OVARY TUMOR; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SALIVA;

AGED; ASCITIC FLUID; CIRCADIAN RHYTHM; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFLAMMATION; INTERLEUKIN-6; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PITUITARY-ADRENAL SYSTEM; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SALIVA;

EID: 84922829589     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.01.010     Document Type: Article

References (46)

1. American Cancer Society Cancer Facts & Figures 2014 2014, American Cancer Society, Atlanta, GA, Available from URL: http://www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf.
2. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 2002, 20:1248-1259.
3. Burger R.A., Grosen E.A., Ioli G.R., Van Eden M.E., Park M., Berman M.L., Manetta A., Disaia P.J., Granger G.A., Gatanaga T. Spontaneous release of interleukin-6 by primary cultures of lymphoid and tumor cell populations purified from human ovarian carcinoma. J. Interferon Cytokine Res. 1995, 15:255-260.
4. Buysse D.J., Reynolds C.F., Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989, 28:193-213.
5. Cella D.F., Tulsky D.S., Gray G., Sarafian B., Linn E., Bonomi A., Silberman M., Yellen S.B., Winicour P., Brannon J., Eckberg K., Lloyd S., Purl S., Blendowski C., Goodman M., Barnicle M., Stewart I., McHale M., Bonomi P., Kaplan E., Taylor S., Thomas C.R., Harris J. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J. Clin. Oncol. 1993, 11:570-579.
6. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 1995, 332:1351-1362.
7. Clevenger L., Schrepf A., Degeest K., Bender D., Goodheart M., Ahmed A., Dahmoush L., Penedo F., Lucci 3rd J., Thaker P.H., Mendez L., Sood A.K., Slavich G.M., Lutgendorf S.K. Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis. Cancer 2013, 119:3234-3241.
8. Clow A., Hucklebridge F., Stalder T., Evans P., Thorn L. The cortisol awakening response: more than a measure of HPA axis function. Neurosci. Biobehav. Rev. 2010, 35:97-103.
9. Cohen L., Cole S.W., Sood A.K., Prinsloo S., Kirschbaum C., Arevalo J.M., Jennings N.B., Scott S., Vence L., Wei Q., Kentor D., Radvanyi L., Tannir N., Jonasch E., Tamboli P., Pisters L. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS ONE 2012, 7:e42324.
10. Cole S.W., Sood A.K. Molecular pathways: beta-adrenergic signaling in cancer. Clin. Cancer Res. 2012, 18:1201-1206.
11. Dantzer R., Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain Behav. Immun. 2007, 21:153-160.
12. Dickinson R.E., Fegan K.S., Ren X., Hillier S.G., Duncan W.C. Glucocorticoid regulation of SLIT/ROBO tumour suppressor genes in the ovarian surface epithelium and ovarian cancer cells. PLoS ONE 2011, 6:e27792.
13. Edgell T., Martin-Roussety G., Barker G., Autelitano D.J., Allen D., Grant P., Rice G.E. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J. Cancer Res. Clin. Oncol. 2010, 136:1079-1088.
14. Flint M.S., Kim G., Hood B.L., Bateman N.W., Stewart N.A., Conrads T.P. Stress hormones mediate drug resistance to paclitaxel in human breast cancer cells through a CDK-1-dependent pathway. Psychoneuroendocrinology 2009, 34:1533-1541.
15. Jeannin P., Duluc D., Delneste Y. IL-6 and leukemia-inhibitory factor are involved in the generation of tumor-associated macrophage: regulation by IFN-γ. Immunotherapy 2011, 3:23-26.
16. Jehn C.F., Kuehnhardt D., Bartholomae A., Pfeiffer S., Krebs M., Regierer A.C., Schmid P., Possinger K., Flath B.C. Biomarkers of depression in cancer patients. Cancer 2006, 107:2723-2729.
17. Kirschbaum C., Hellhammer D.H. Salivary cortisol in psychoneuroendocrine research: recent developments and applications. Psychoneuroendocrinology 1994, 19:313-333.
18. Kraemer H.C., Giese-Davis J., Yutsis M., O'Hara R., Neri E., Gallagher-Thompson D., Taylor C.B., Spiegel D. Design decisions to optimize reliability of daytime cortisol slopes in an older population. Am. J. Geriatr. Psychiatry 2006, 14:325-333.
19. Kulbe H., Chakravarty P., Leinster D.A., Charles K.A., Kwong J., Thompson R.G., Coward J.I., Schioppa T., Robinson S.C., Gallagher W.M., Galletta L., Australian Ovarian Cancer Study Group, Salako M.A., Smyth J.F., Hagemann T., Brennan D.J., Bowtell D.D., Balkwill F.R. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res. 2012, 72:66-75.
20. Kurman R.J. Origin and molecular pathogenesis of ovarian high-grade serous carcinoma. Ann. Oncol. Suppl. 2013, 10. x16-21.
21. Lamkin D.M., Lutgendorf S.K., Lubaroff D., Sood A.K., Beltz T.G., Johnson A.K. Cancer induces inflammation and depressive-like behavior in the mouse: modulation by social housing. Brain Behav. Immun. 2011, 25:555-564.
22. Lane D., Matte I., Rancourt C., Piché A. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients. BMC Cancer 2011, 11:210.
23. Lutgendorf S.K., Weinrib A.Z., Penedo F., Russell D., DeGeest K., Costanzo E.S., Henderson P.J., Sephton S.E., Rohleder N., Lucci J.A., Cole S.W., Sood A.K., Lubaroff D.M. Interleukin-6, cortisol, and depressive symptoms in ovarian cancer patients. J. Clin. Oncol. 2008, 26:4820-4827.
24. Mavroudis P.D., Scheff J.D., Calvano S.E., Lowry S.F., Androulakis I.P. Entrainment of peripheral clock genes by cortisol. Physiol. Genomics 2012, 44:607-621.
25. Obata N.H., Tamakoshi K., Shibata K., Kikkawa F., Tomoda Y. Effects of interleukin-6 on in vitro cell attachment, migration and invasion of human ovarian carcinoma. Anticancer Res. 1997, 17:337-342.
26. Offner F.A., Obrist P., Stadlmann S., Feichtingera H., Klinglerb P., Heroldc M., Zwierzinac H., Hittmaira A., Mikuza G., Abendsteind B., Zeimete A., Marth C. IL-6 secretion by human peritoneal mesothelial and ovarian cancer cells. Cytokine 1995, 7:542-547.
27. Pace T.W., Miller A.H. Cytokines and glucocorticoid receptor signaling. Relevance to major depression. Ann. N. Y. Acad. Sci. 2009, 1179:86-105.
28. Radloff L.S. The CES-D scale: a self-report depression scale for research in the general population. Appl. Psychol. Meas. 1977, 1:385-401.
29. Reinartz S., Schumann T., Finkernagel F., Wortmann A., Jansen J.M., Meissner W., Krause M., Schwörer A.M., Wagner U., Müller-Brüsselbach S., Müller R. Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse. Int. J. Cancer 2014, 134:32-42.
30. Rhen T., Cidlowski J.A. Antiinflammatory action of glucocorticoids - new mechanisms for old drugs. N. Engl. J. Med. 2005, 353:1711-1723.
31. Rich T., Innominato P.F., Boerner J., Mormont M.C., Iacobelli S., Baron B., Jasmin C., Lévi F. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin. Cancer Res. 2005, 11:1757-1764.
32. Schauer I.G., Zhang J., Xing Z., Guo X., Mercado-Uribe I., Sood A.K., Huang P., Liu J. Interleukin-1β promotes ovarian tumorigenesis through a p53/NF-κB-mediated inflammatory response in stromal fibroblasts. Neoplasia 2013, 15:409-420.
33. Schrepf A., Clevenger L., Christensen D., DeGeest K., Bender D., Ahmed A., Goodheart M.J., Dahmoush L., Penedo F., Lucci J.A., Ganjei-Azar P., Mendez L., Markon K., Lubaroff D.M., Thaker P.H., Slavich G.M., Sood A.K., Lutgendorf S.K. Cortisol and inflammatory processes in ovarian cancer patients following primary treatment: relationships with depression, fatigue, and disability. Brain Behav. Immun. 2013, 30(Suppl.):S126-S134.
34. Sephton S.E., Sapolsky R.M., Kraemer H.C., Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J. Natl. Cancer Inst. 2000, 92:994-1000.
35. Sephton S.E., Lush E., Dedert E.A., Floyd A.R., Rebholz W.N., Dhabhar F.S., Spiegel D., Salmon P. Diurnal cortisol rhythm as a predictor of lung cancer survival. Brain Behav. Immun. 2013, 30(Suppl.):S163-S170.
36. Silverman M.N., Sternberg E.M. Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction. Ann. N.Y. Acad. Sci. 2012, 1261:55-63.
37. Singer J.D., Willett J.B. Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence 2003, Oxford University Press, New York.
38. Sood A.K., Buller R.E. Drug resistance in ovarian cancer: from the laboratory to the clinic. Obstet. Gynecol. 1998, 92:312-319.
39. Stone A.A., Schwartz J.E., Smyth J., Kirschbaum C., Cohen S., Hellhammer D., Grossman S. Individual differences in the diurnal cycle of salivary free cortisol: a replication of flattened cycles for some individuals. Psychoneuroendocrinology 2001, 26:295-306.
40. Tokunaga H., Takebayashi Y., Utsunomiya H., Akahira J., Higashimoto M., Mashiko M., Ito K., Niikura H., Takenoshita S., Yaegashi N. Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet. Gynecol. Scand. 2008, 87:1060-1070.
41. Tsigos C., Chrousos G.P. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J. Psychosom. Res. 2002, 53:865-871.
42. Volden P.A., Conzen S.D. The influence of glucocorticoid signaling on tumor progression. Brain Behav. Immun. 2013, 30(Suppl.):S26-S31.
43. Weinrib A.Z., Sephton S.E., Degeest K., Penedo F., Bender D., Zimmerman B., Kirschbaum C., Sood A.K., Lubaroff D.M., Lutgendorf S.K. Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer 2010, 116:4410-4419.
44. Yang X., Wood P.A., Oh E.Y., Du-Quiton J., Ansell C.M., Hrushesky W.J. Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res. Treat. 2009, 117:423-431.
45. Yang M., Kim J., Kim J.S., Kim S.H., Kim J.C., Kang M.J., Jung U., Shin T., Wang H., Moon C. Hippocampal dysfunctions in tumor-bearing mice. Brain Behav. Immun. 2014, 36:147-155.
46. Zhang C., Marmé A., Wenger T., Gutwein P., Edler L., Rittgen W., Debatin K.M., Altevogt P., Mattern J., Herr I. Glucocorticoid-mediated inhibition of chemotherapy in ovarian carcinomas. Int. J. Oncol. 2006, 28:551-558.